Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (åpner nytt vindu)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Kilde‎: Ann Intern Med 2008;148(12):939-55.

Arkiv‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (åpner nytt vindu)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (åpner nytt vindu)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Kilde‎: Am J Hematol 2000;64(1):26-31.

Arkiv‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (åpner nytt vindu)

Hydroxyurea for the treatment of sickle cell anemia. (åpner nytt vindu)

Platt OS.

Kilde‎: N Engl J Med 2008;358(13):1362-9.

Arkiv‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (åpner nytt vindu)

Clinical effectiveness of decitabine in severe sickle cell disease. (åpner nytt vindu)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Kilde‎: Br J Haematol 2008;141(1):126-9.

Arkiv‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (åpner nytt vindu)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (åpner nytt vindu)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Kilde‎: Blood 2010;115(12):2354-63.

Arkiv‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (åpner nytt vindu)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (åpner nytt vindu)

Hirst C, Owusu-Ofori S.

Kilde‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Arkiv‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (åpner nytt vindu)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (åpner nytt vindu)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Kilde‎: Lancet Haematol 2021;8(5):e323-33.

Arkiv‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (åpner nytt vindu)

Sickle cell disease. (åpner nytt vindu)

Meremikwu MM, Okomo U.

Kilde‎: BMJ Clin Evid 2011;02:2402.

Arkiv‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (åpner nytt vindu)

A phase 3 trial of l-glutamine in sickle cell disease. (åpner nytt vindu)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Kilde‎: N Engl J Med 2018;379(3):226-35.

Arkiv‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (åpner nytt vindu)

Malaria chemoprophylaxis in sickle cell disease. (åpner nytt vindu)

Oniyangi O, Omari AA.

Kilde‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Arkiv‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (åpner nytt vindu)